-
Randomized Phase 2 Study of Erdafitinib vs Investigator Choice of Chemo in Subjects Who Received BCG and Recurred With HR NMIBC (42756493BLC2003)
The purpose of the study is to determine the safety and efficacy of erdafitinib in subjects with Non-Muscle-Invasive Bladder Cancer (NMIBC) and fibroblast growth factor ... -
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab TAR-200 Alone or Cetrelimab Alone in Participants with High-Risk Non- Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin (BCG) who are Ineligible for or Elected Not to Undergo Radical Cystectomy
The purpose of the study is to determine the efficacy and safety of TAR-200 in combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in participants ... -
A Multicenter Clinical Trial of Intravesical Bacillus Calmetter-Guerin (BCG) in combination with ALT-803 in Patients with BCG Unresponsive High Grade non-Muscle Invasive Bladder Cancer
The purpose of the study is to assess effectiveness and safety of the intravesical BCG (Bacillus Calmetter-Guerin) in combination with ALT-803 in patients with BCG ... -
Site for 10144 - A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects
The purpose of the study is to determine if olaparib works in treating patients with urothelial cancer with deoxyribonucleic acid (DNA)-repair defects that has ... -
A Phase II Open Label Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1 / PD-L1 Based Immunotherapy
If you have been diagnosed with urothelial cancer that has progressed or returned, you may be qualified for this Phase 2 study. The main goal ...